The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

Young, Empowered, and Strong (YES), a mobile health intervention, was linked to improved general and cancer-specific ...

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

Onc Nurse On Call is the new podcast by Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, AOCN, and ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk ...

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

From clinical trials, to psychosocial needs, to care transitioning, adolescent and young adult patients with cancer face ...

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in ...

The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of ...

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...